Clinical Trial Update: Stellate Ganglion Block for COVID-induced Parosmia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating stellate ganglion block for COVID-19-induced parosmia has completed, with results posted on 2025-11-10.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Covid-19-induced Parosmia

Drugs mentioned

• Stellate Ganglion Block

Snippet

Sponsor: Washington University School of Medicine | Conditions: COVID-19-Induced Parosmia | Phase 2 | Status: COMPLETED | Results posted: 2025-11-10